ERBB2 and lung carcinoma: Acquired drug resistance by genetic mutation or down regulation of targeted proteins, such as HER2 mutation in Herceptin-treated metastatic breast cancer patients52, and EGFR mutation in Gefitinib-treated lung cancer patients53, and others54,55, is an important vulnerability of many molecular-targeted anti-tumor therapies.